<DOC>
	<DOC>NCT00381472</DOC>
	<brief_summary>The purpose of this double-blind, placebo controlled study is to evaluate the safety and effectiveness of an investigational Parkinson's disease drug in patients with advanced disease who are not well-controlled on their L-dopa medication.</brief_summary>
	<brief_title>Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Idiopathic Parkinson's disease Modified Hoehn and Yahr Scale Stages II IV Stable dose of Ldopa for at least 4 weeks prior to screening. Lack of control with Ldopa therapy. Women of childbearing potential must use a clinically accepted form of birth control. Significant and/or uncontrolled medical conditions (excluding Parkinson's disease) within 3 months of screening. Any abnormality, at screening, that is considered clinically relevant by the Investigator. Dementia Use of dopamine agonists within 4 weeks of screening visit. Participation in other investigational drug studies.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Adjunctive Therapy with L-dopa</keyword>
</DOC>